We are living in a time when increasing attention is being paid to the legal ramifications of medical practice. The subsequent article, Tardive Dyskinesia: Legal and Preventive Aspects by Shriqui et al (1) in this issue, draws attention to five recent legal judgements in the United States that related to the syndrome of tardive dyskinesia (TD). Medical shortcomings cited by the court include the following: failure to obtain informed consent for neuroleptic treatment, lack of a clearly documented indication for maintenance neuroleptic therapy, inappropriate continuation of neuroleptics after the appearance of dyskinetic movements, and the use of excessive doses of neuroleptic medication.
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Fundamental to any consideration of the medical-legal aspects of TD is the question: to what extent can one specify, in any individual case, a causal relationship between neuroleptic exposure and the presence of involuntary choreoathetotic movements? The answer is by no means straightforward. On the one hand, TD has long been recognized as a late onset complication of neuroleptic therapy. On the other hand, involuntary movements indistinguishable from those of TD are frequently seen in patients who have never been exposed to neuroleptics. This is particularly true of patients with major psychoses, neurodegenerative diseases or a neurodevelopmental disorder. Owens and colleagues (2), for example, identified 47 schizophrenic patients who had never received neuroleptic medication, and found that 25 of these (53%) exhibited involuntary movements virtually identical to those seen in TD. In an earlier study, Villeneuve et al (3) found that five of 16 (31 %) neuroleptic-naive patients with chronic schizophrenia showed typical orofacial dyskinesia. Delwaide and Desseilles (4) reported that oral-facial dyskinesia was present in 39 % of the 185 patients with senile dementia whom they examined. Stone and co-workers (5) studied 417 mentally handicapped patients who had not been exposed to neuroleptic drugs and found that 48 % had evidence of an involuntary movement disorder. What these, and numerous similar studies, indicate is that, in an unknown but by no means trivial proportion of cases, the involuntary movements observed in patients treated with neuroleptics may be attributable to something other than long term exposure to the medications. In other words, abnormal choreoathetotic movements in a patient treated with neuroleptics may not necessarily represent TD. In the medicallegal context, this means that the presence or absence of involuntary movements should be carefully documented, Can. J. Psychiatry Vol. 35, October 1990 573 preferably using a standardized measurement such as the Abnormal Involuntary Movement Scale (AIMS) (6, 7) , in all patients who are about to be started on neuroleptic therapy.
Knowledge of the factors which determine the vulnerability of an individual patient to TD is a critical issue from a medical-legal standpoint, as well as from the point of view of sound medical practice. Foremost among these is age. There seems to be little doubt that the prevalence and severity of TD increase with advancing age, particularly among those with chronic neuropsychiatric illnesses. In addition women appear to be more prone to developing TD than men. This difference is largely restricted to the elderly, however, and is much less impressive in younger populations. Common sense suggests that TD is related to the duration of neuroleptic exposure and the dose used, but this has been difficult to demonstrate in studies of the chronically ill. Perhaps the most convincing data come from the prospective study of Kane et al (8) , who found that the incidence ofTD increased with the duration of neuroleptic exposure over an eight year period. There is little information on the extent to which different neuroleptics differ in their capacity to induce TD.
Another important question is whether any particular diagnostic groups show an increased tendency to develop TD. The balance of the evidence available to date indicates that patients with affective disorder are at greater risk. Patients with cognitive dysfunction appear to be particularly susceptible to developing TD when exposed to neuroleptics, as are those with radiological evidence of structure brain pathology. A history of severe extrapyramial side-effects of neuroleptics may also indicate increased vulnerability to the development of TD. Each of these putative risk factors needs to be considered when attempting to weigh the risks against the potential benefits of neuroleptics in a given case.
It has been clearly established that the clinical manifestations of TD can remit, and that the likelihood of such remission appears to diminish with age. Remission can occur even when involuntary movements have persisted for more than two years following neuroleptic withdrawal (9) . One must therefore by very cautious when deciding whether or not the TD in an individual case is irreversible. Kane and colleagues (8) found that 40% of the subjects in their prospective therapy, although in only about half of these cases did the involuntary movements persist for more than six months. Factors associated with favourable prognosis included: the younger age of the patient, shorter exposure to neuroleptics and the use of lower doses of neuroleptics following the emergence ofTD. A lesson to be learned from this is that one should make efforts to reduce the dosage of neuroleptics once evidence of TD has declared itself.
Methodological shortcomings have compromised most efforts to estimate the prevalence ofTD, with various studies reporting prevalence rates ranging from 0.5 % to 67.0 % or higher. Among the factors contributing to such variability in the estimation of prevalence are the following: the criteria according to which TD is diagnosed, the demographic and diagnostic composition of the patient population, and the extent to which ongoing neuroleptic treatment may be "masking" underlying TD. The latter two factors pose particular difficulties. The probability that neuroleptics will cause TD in patients with a given disorder cannot reasonably be estimated without knowing something about the baseline level of involuntary movements that could be expected in a comparable population of untreated patients. As noted above, this' 'baseline" level of dyskinesia can, in some disorders, involve 50% or more of the neuroleptic-naive population. As for "masking", it is inevitable that many of the patients who should be studied in order to ascertain the prevalence of TD cannot ethically have their neuroleptics discontinued. Under these circumstances, problems arise because the neuroleptics may be suppressing underlying TD and thereby masking the true prevalence of TD in patients treated with neuroleptics.
A difficult issue raised in several of the cases discussed in the paper by Shriqui et al is that of informed consent. Psychiatrists are understandably concerned about the ability of psychotic patients to make informed decisions about treatment. Added to this is the concern that a discussion of drug side-effects may reduce the already tenuous compliance that many psychotic patients have with their drug regimen. This concern was addressed in a study of 25 schizophrenic outpatients by Munetz and Roth (10) , who found that it was possible for clinicians to openly discuss the risks and benefits of neuroleptic treatment without jeopardizing the patient's compliance. The importance of documentation is repeatedly highlighted in medical-legal cases. Clinicians must document clearly the rationale for prescribing neuroleptics in an individual case, particularly if the diagnosis is one for which potential alternative treatments are available. It is equally important to note any discussions with the patient concerning neuroleptic side-effects. In view of the widespread prevalence of dyskinesia among unmedicated patients with psychoses, neurodegenerative diseases or neurodevelopmental illnesses, physicians should always look for and document any involuntary movements that are present before beginning neuroleptic therapy. Finally, it is important to continue watching for and documenting any abnormal movements that arise during the course of neuroleptic treatment. This documentation will ensure a clear record in the event of litigation. Perhaps more importantly, by drawing the physician's attention to the possible presence of involuntary movements, such documentation may increase the likelihood that appropriate measures will be taken to reduce the risk of permanent TD.
